1. Pink Sheet

The Short And Controversial Life Of Zohydro Comes To An End

 
• By Brenda Sandburg

US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.

Zohydro ER tombstone
Zohydro (hydrocodone bitartrate) has been withdrawn from the market • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

The quiet end for Zohydro ER – buried in a list of drugs whose approvals are being withdrawn by the US FDA – belies the turmoil the opioid created for the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership